# Efficacy of Cannabinoids in Improving Nutritional Outcomes in Chemotherapy Patients > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/efficacy-of-cannabinoids-in-improving-nutritional-outcomes-in-chemotherapy-patients/ > **Published:** 2026-08-19T07:13:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:16:12-04:00 > **Clinical Summary:** Evidence on cannabis chemotherapy cachexia and appetite stimulation. Clinical review of THC/CBD efficacy in cancer patients. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerResearchTHCCBDSafetyDosingAnxiety Why This Matters Clinicians treating cancer patients experiencing chemotherapy-induced appetite loss and cachexia now have emerging evidence supporting cannabinoid use as an adjunctive intervention to improve nutritional intake and body weight maintenance. This research provides a pharmacological option for patients who fail conventional antiemetic and appetite stimulant medications, potentially improving treatment tolerance and [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) during active chemotherapy. Understanding cannabinoid efficacy and appropriate dosing allows clinicians to make informed recommendations and monitor outcomes in this vulnerable population. Clinical Summary This clinical trial evaluated cannabis capsules containing THC and CBD for improving nutritional outcomes in chemotherapy patients experiencing [cancer-related cachexia](https://cedclinic.com/thc-triggers-appetite-brain-cannabis-hunger-study/) and appetite loss. The study design appears to assess whether cannabinoid treatment can reverse weight loss and enhance caloric intake in this vulnerable population, addressing a significant symptom burden that limits treatment tolerance and [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). The findings are directly relevant to oncology practice, as [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) and weight maintenance are important supportive care goals that may improve chemotherapy tolerance and patient outcomes. If efficacy is demonstrated, cannabis-based products could offer an evidence-based option for managing chemotherapy-induced anorexia when conventional antiemetics or appetite stimulants prove insufficient. Clinicians treating cancer patients should monitor emerging evidence on cannabinoid efficacy in cachexia, as positive results could expand the supportive care toolkit and inform counseling about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in this population. The practical implication is that oncologists may soon have data to support or refute recommending THC/CBD products as part of comprehensive nutritional management for chemotherapy patients with significant weight loss. Dr. Caplan’s Take “We have some promising early signals that cannabinoids may help with appetite and nutritional intake in chemotherapy patients, but we need to see these results replicated in larger, well-controlled trials before I’d feel confident making this a standard recommendation in my practice.” Clinical Perspective 💊 While cannabinoids show theoretical promise for stimulating appetite and potentially improving nutritional intake in chemotherapy patients experiencing cachexia, clinicians should interpret efficacy claims cautiously given the limited robust evidence base and heterogeneity in trial designs, dosing regimens, and patient populations studied to date. The clinical utility of cannabis for this indication remains complicated by variable cannabinoid formulations, inconsistent outcome measurement across studies, and the difficulty isolating [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) from other physiologic effects or placebo responses. Additionally, potential drug interactions with chemotherapy agents and antiemetics, variable metabolism across patients, and legal or institutional barriers to access may limit practical implementation. For patients with severe [cancer-related anorexia](https://cedclinic.com/cannabis-appetite-effects-benefit-no-appetite/) and cachexia refractory to conventional interventions, a cautious, individualized discussion acknowledging the preliminary nature of the evidence while exploring available pharmaceutical options (such as megestrol acetate) may be most appropriate at this time, 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Efficacy%20of%20Cannabinoids%20in%20Improving%20Nutritional%20Outcomes%20in%20Chemotherapy%20Patients%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74337)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74337)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Efficacy%20of%20Cannabinoids%20in%20Improving%20Nutritional%20Outcomes%20in%20Chemotherapy%20Patients%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74337)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.cureus.com/articles/476813-efficacy-of-cannabinoids-in-improving-nutritional-outcomes-in-chemotherapy-patients-a-scoping-review](https://www.cureus.com/articles/476813-efficacy-of-cannabinoids-in-improving-nutritional-outcomes-in-chemotherapy-patients-a-scoping-review) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).